New technologies delivered to your inbox Subscribe
2013-157 – Application Enhance transduction and transgene expression of Adeno-associated virus (AAV) vectors using U2 snRNP spliceosome inhibitors Value Proposition AAV has become one of the leading gene delivery vectors in clinical development. Gene therapy using recombinant AAV has been demonstrated to be safe and well-tolerated in virtually every clinical setting in which it has been used.... Read More
2015-347 – Mayo Clinic has developed compositions and methods for detecting soluble PD-L1
2015-311 – Mayo Clinic has discovered that HEATR1 is a novel Akt regulator and a predictor for chemoradioresistance.
2015-312 – Mayo Clinic has discovered that the Parkin protein is a mitotic regulator. Cancer cells with deficiency or mutations in Parkin have an increase in mitotic regulator expression leading to tumorigenesis and an increase in sensitivity of Pk1 and Aurora kinase inhibitors. This newly identified mechanism has revealed that Parkin mutations may be used as a biomarker for measuring the sensitivity of... Read More
2015-164 – Mayo Clinic has discovered that WSB1 can be used as a diagnostic marker for tumor metastasis and a therapeutic target.
2013-237 – Bim is a biomarker for PD-1 and PD-L1 therapies.
Methods of Treating Cancer by Using PD1 and PD-L1 inhibitors by Using Soluble PD-L1 Levels as a Biomarker
2008-042 – Mayo Clinic has patent rights claiming methods of using PD1 or PD-L1 antibodies to treat cancer by using soluble PD-L1 levels in the serum as a biomarker.
2004-222 – Mayo Clinic has patent rights claiming obesity devices.
2004-106 – Mayo Clinic as designed an Endoscopic Pneumatic Assist Device (EPAD) to help patients with weight loss and maintenance. The EPAD technology induces weight loss by creating a physical/obstructive barrier to the passage of nutrients through the pylorus. Additionally, the device induces malabsorption due to the attached optioal malbsorptive sleeve in the proximal small bowel.Finally, the use of... Read More
2003-132 – Mayo Clinic has patent rights claiming methods of detecting the autoantibody associated with NMO.
2004-239 – Mayo Clinic has patent rights claiming the use of PD1 and PD-L1 antibodies to treat cancer. The patent rights also include diagnostic and prognostic claims.
2002-064 – Mayo Clinic has patent rights broadly claiming the use of PD-L1 antibodies to treat cancer.
1999-098 – Mayo Clinic has patent rights broadly claiming PD-L1 antibodies along with other PD-L1 related fundamental patent claims.
2017-235 – Mayo Clinic has discovered that novel STAT3 inhibitors would potentially be a therapeutic treatment in pediatric tumor Diffuse Intrinsic Pontine Glioma (DIPG). Novel STAT3 inhibitors selectively killed tumor cells found in DIPG.
2017-036 – Mayo Clinic has discovered that inhibition of stearoyl-CoA desaturase 1, SCD1 - a key enzyme fatty acid metabolism, in combination with PD1/PD-L1 inhibition enhances T cell based cancer immunotherapy.
2017-176 – Mayo Clinic has discovered that novel SCD1 inhibitors can be used to treat liver cancer.
2016-386 – Mayo Clinic has discovered the UFM1 signaling pathway as a biomarker/therapeutic target in cancer. UFM1 is an Ub-like molecule needed for ATM activation and DNA damage response. Inhibiting the pathway could sensitize cancer cells to radiation and chemotherapy.
2016-117 – Mayo Clinic has discovered that the use of USP7 inhibitors sensitize HER2+breast cancer cells to existing HER2+ therapies.
2016-055 – Mayo Clinic has discovered the functional roles for DUB3, an ubiquitin specific protease, and CDK4/6 inhibitors, in their ability to regulate cancer metastasis. CDK4/6 inhibitors blocked triple-negative breast cancer metastasis.
2015-066 – Mayo Clinic has discovered that USP10, an ubiquitin protease, deubinquinates AMPK and inhibits mTOR activity. Activating USP10 could have therapeutic effects in treating diabetes and cancer.
Therapeutic Modulation of the MoCo Biosynthesis Pathway to Protect Neurons and Axons from Inflammation-Induced Injury
2014-299 – Mayo Clinic has developed an innovative therapeutic strategy to use molybdenum cofactor (MoCo) to treat neurological inflammatory disease.
2014-207 – Mayo Clinic has discovered a therapeutic pathway to target PD-L1 (a.k.a. B7-H1) positive tumors. Inhibition of DNA-PKcs function restores the sensitivity of PD-L1 positive tumors to chemotherapy by two fold.
2016-389 – The treatment of cancer patients is very complex, with treatment decisions made all the more difficult in patients with multiple comorbidities and compounding drug toxicities. Front-line treatments can be straight forward, but disease relapses often require input and expertise from multidisciplinary teams. These teams utilize their collective experience in disease treatment and patient... Read More
Innovative Asthma Ascertainment by Using Natural Language Processing Algorithm Enabling Automated Chart Review
2016-271 – Mayo Clinic investigators have developed a novel natural language processing (NLP) algorithm designed to automate chart review in order to ascertain asthma status and date of onset by using free text from a patient’s medical record. An initial validation of this algorithm in a patient cohort showed a sensitivity and specificity of 89% and 97% (respectively) when compared to asthma status... Read More
2016-451 – No standard tools are currently available to measure a patient’s progress in regards to their care plan or discharge goals. Determination of patient status is dependent upon delving into multiple medical documents, a process that is cumbersome and costly. Mayo Clinic investigators have developed the Electronic Case Management Tool to simplify the ascertainment of patient status and provide... Read More
2016-135 – The advent of next-generation sequencing has opened the door to widespread identification of somatic mutations in tumor genomes. These somatic mutations can be utilized to identify “true clonal mutations”, or those that are responsible for driving tumor growth in an individual, and therefore could be useful in the identification of therapeutic targets. The primary issue in the identification... Read More
2014-379 – The global hearing aid market is a multi-billion dollar industry. Although this industry is lucrative, market penetration is very low, primarily due to high cost and the stigma associated with hearing aids. These barriers limit the number of users that could benefit from hearing assistance technologies. Mayo Clinic investigators have developed a low-cost, non-invasive hearing solution that... Read More
2016-477 – The Establishment of primary care provider panels is a complex and difficult process. This process is made all the more difficult in the transition from fee-for service to value-based reimbursement. One of the primary focuses of value-based reimbursement is documenting the overall care of a patient, and a major component of this is assigning each patient to a primary care provider. Mayo... Read More
2014-026 – A peak velocity estimator algorithm for flow phantom spectra. This peak velocity estimator has been adapted for use with Doppler velocity spectra from string phantoms.
2013-186 – The PET imaging agent F-18 sodium hexafluorophosphate (Na[18F]PF6) for hNIS expression in tumors.
2010-312 – The invention relates to the treatment of meningiomas using a composition including a cytotoxic agent and a compound selected from phenylbenzothiazole derivatives, stilbene derivatives, and biphenylalkyne derivatives.
2015-159 – The Anesthesia Auditing Program Software provides quality improvement for anesthesia medication administration. The program audits all anesthesia medication transactions across a number of databases. The program has demonstrated significant improvements in patient safety, financial charge capture, drug diversion prevention, and documentation accuracy. The program has the ability to work or... Read More
Enhancing the Accuracy, Efficiency and Retention of Reading by Health Care Providers Using Electronic Medical Record Systems to Improve the Safety, Effectiveness and Value of Health Care Services
2014-031 – This technology applies and integrates significant, computationally intensive reading tools into electronic medical records (EMR) systems to enhance medical reading performance by individuals who, in any other context, would not be aware of or concerned about their reading performance compared to their peers in their working group. The technology includes: 1. A medical language database... Read More
2012-185 – This technology includes a suite of patents which advance text enhancement methods and apparatus for the presentation of text for improved human reading for the electronic medical record (EMR). The method includes extracting text specific attributes from machine readable text and varying the text presentation in accordance with the attributes. Suite of patents include: -US Patent... Read More
2012-209 – Mayo Clinic researchers have developed methods and materials for treating cancer through the use of antigen combinations. For example, Vesicular Stomatitis Virus (VSV) vectors designed to express a GNAQ antigen, a TYRP1 anti-gen, and an N-RAS antigen can be used to reduce the number of cancer cells (e.g., uveal melanoma cells) within a mammal. In some cases, VSV vectors designed to express... Read More
1998-039 – Through the use of gene targeting in mouse embryonic stem (ES) cells we have successfully generated a line of mice deficient in eosinophil granule major basic protein-1 (mMBP-1). These mice would be useful in drug discovery programs directed toward developing treatments for asthma, allergy, inflammation and a variety of eosinophil-related disorders. PMID: 11067904
Combining Single Domain Antibody Fragments and Mass Spectrometry as a Diagnostic Test for Patients with Plasma Cell Dyscrasias
2015-146 – Mass spectra of proteins isolated using single domain antibody fragments (SDAF) with affinity for immunoglobulins are used to identify, quantitate, and establish heavy and light chain pairings of M-proteins using MALDI-TOF mass spectrometry. The invention utilizes the unique molecular mass and structure of single domain antibody fragments and the unique molecular mass distributions of heavy... Read More
2015-151 – Several novel naturally processed and HLA presented influenza A/H5N1-derived peptides from a class I HLA-A0201 molecules have been identified. A mass spectrometry approach was used to identify five influenza peptides from a B-cell line (homozygous for HLA-A0201) after infection with influenza A/H5N1 virus. The immunologic relevance and specificity of these identified influenza-derived... Read More
2015-065 – Mass accuracy is used to measure free light chains in serum, urine, CSF and body fluid. The mass accuracy allows for direct quantitation of each kappa and lambda light chain. This technique is useful in the diagnosis and prognosis of multiple myeloma, MGUS, B-CLL, Waldenstroms macrogloblinemia, AL amyliodosis, non-secretory myeloma and for distinguishing an auto-immune response from a... Read More
2015-064 – High mass accuracy is used to measure Igs in CSF and serum. The mass accuracy allows for direct quantitation of each kappa and lambda light chain and can be used as a surrogate marker for active clonal B-cells. This method increases the accuracy of clone matching between serum and CSFand utilizes top-down mass spectrometry which allow for fragmentation patterns to be used for absolute... Read More
2014-321 – TGR5 antagonist for the treatment of cholangiopathies including polycystic liver disease.
2014-330 – An adult hypomorphic model of Propionic acidemia (PA) in Pcca− mice using a transgene bearing an A138T mutant of the human PCCA protein. Pcca−/−(A138T) mice have 2% of wild-type PCC activity, survive to adulthood, and have elevations in propionylcarnitine, methylcitrate, glycine, alanine, lysine, ammonia, and markers associated with cardiomyopathy similar to those in patients with PA. Data... Read More
2014-229 – Computer modeling followed by synthesis of novel compounds and testing for stearoyl CoA desaturase 1 (SCD1) specific growth inhibition of cancer cells has led to the identification of four novel lead SCD1 inhibitors.
2014-148 – The SR4G transgenic zebrafish stress response reporter line utilizes a tandem array of glucocorticoid response element sequences to drive expression of a short half-life green fluorescent protein when bound by active glucocorticoid receptors. High-resolution imaging and qRT-PCR have been used to characterized the spatiotemporal responses of this reporter line following exposure to exogenous... Read More
2014-102 – The device harvests a small strip of rectus fascia (1 x 5 cm) by simultaneously dilating the rectus fascial, stapling and then cutting the fascia. The device is small enough to fit through a 3-5 cm lower abdominal incision and articulates to an adjustable angle to account for possible patient obesity.
2014-055 – Exon 41 of LRRK2 is floxed, thus LRRK2 can be removed by cre-mediated deletion. Genotype/Phenotype: homozygous LRRK2loxp/ LRRK2loxp, phenotype would be dependent on which cells express Cre after crossing. Utility: Parkinson’s Disease Research PMID: 22647713
2013-206 – This invention has benefit over other methods since it directly quantitates the mAb without the need for interaction with the antigen. By monitoring tryptic peptides from the unique variable regions of the therapeutic mAb and comparing them to the constant regions of a non-human antibody added as an internal standard, the mAb can be measured. This method is superior to other methods using... Read More
2012-285 – A method to identify if an M-spike contains either a kappa or lambda light chain has been discovered through the use of liquid chromatography tandem mass spectrometry (LC-MS/MS).
2012-139 – In normal healty individuals, the plasma cells produce numerous immunoglobulins each with its own unique protein sequence and hence a unique mass. When examined together, the distribution of the masses forms a Gaussian distribution. Patients whom have plasma cells that overproduce immunoglobulins (M-proteins) are at risk for developing serious diseases such as multiple myeloma. Currently,... Read More
2012-062 – Broad patent claims have issued claiming methods for treating renal cell carcinoma by using SCD1 inhibitors and are available for licensing.